Medical AI Future: Sustainable Reimbursement Strategies

By HEOR Staff Writer

May 6, 2024

Introduction

Artificial Intelligence (AI) in medicine has the potential to significantly enhance patient care, yet its widespread adoption is very dependent on sustainable reimbursement models. In a recent article, authors examine how fee-for-service (FFS) and value-based care (VBC) can facilitate the scaling of medical AI, and they propose strategies to align stakeholder interests.

The Challenge of Medical AI Reimbursement

Medical AI’s promise to enhance patient outcomes faces a significant obstacle: achieving sustainable reimbursement. Although the U.S. healthcare system offers a blueprint for this process, the path to reimbursement is filled with multiple complexities, necessitating the collaboration of diverse stakeholders.

Fee-for-Service: A Traditional Approach

FFS remains a prevalent model where medical AI services are billed similarly to other medical interventions. While this model offers transparency and can provide financial sustainability, it is not without risks, such as potential over utilisation and exacerbation of health disparities.

The Shift to Value-Based Care

VBC is reshaping the reimbursement landscape by focusing on patient outcomes and efficiency. This model accounts for a substantial portion of U.S. healthcare spending and offers fewer regulatory constraints. However, the real-world impact of VBC on cost and quality of care remains mixed.

Emerging Models and Real-World Cases

New reimbursement models are emerging, such as revenue-sharing approaches akin to the Medicare Part B drug payment system. Real-world cases, like autonomous AI for diabetic eye examinations, demonstrate how FFS and VBC can be effectively leveraged for reimbursement.

Accelerating Adoption Through Strategic Reimbursement

To expedite the adoption of medical AI, creators must navigate the reimbursement landscape effectively. This may involve pursuing FFS pathways, such as establishing a Current Procedural Terminology (CPT) code, or integrating into existing VBC frameworks like Merit-Based Incentive Payment Systems/ Healthcare Effectiveness Data and Information Set (MIPS/HEDIS).

Conclusion

The journey towards sustainable reimbursement for medical AI is complex, yet essential for its successful integration into healthcare. By understanding and utilising current FFS and VBC models, stakeholders can ensure that medical AI reaches its full potential in improving patient outcomes.

Reference url

Recent Posts

Enhertu Breast Cancer Treatment Gains FDA Approval in Neoadjuvant and Adjuvant Settings

By João L. Carapinha

May 18, 2026

Enhertu breast cancer treatment has secured FDA approval for neoadjuvant use in adults with HER2-positive Stage II or III disease before surgery, followed by taxane plus trastuzumab and pertuzumab, and for adjuvant therapy in patients with residual invasive disease after prior trastuzumab-based r...
Pharmaceutical Onshoring Agreements: Navigating Tariff Relief and National Security Policies
The US Bureau of Industry and Security published formal procedures enabling manufacturers of patented pharmaceutical products to apply for company-specific pharmaceutical onshoring agreements with the Department of Commerce. These agreements allow qualifying firms to secure a reduced Section 232 ...
Dynamic Risk Stratification in Thromboembolism Prevention for Cancer Patients
Dynamic risk stratification enables more precise forecasting of venous thromboembolism risk in cancer patients by continuously updating predictions as new clinical data emerge. A transformer-based deep learning model was developed using longitudinal electronic health records from the U.S. Veteran...